PO-1096 Safety of concurrent TDM-1 and radiotherapy for patients with residual HER2-positive breast cancer. (August 2021) - Becherini, C.; Stocchi, G.; Visani, L.; De Santis, M.C.; Colciago, R.R.; Pedretti, S.; Magrini, S.M.; Nuzzo, M.; Genovesi, D.; Ursini, L.A.; Bonanni, A.; Ippolito, E.; et al.